Related Experiment Videos
Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node?
W C Liang1, B J Sickle-Santanello, T A Nims
1Department of Surgical Oncology, Grant Medical Center, Suite 911, Baldwin Tower, 300 E. Town Street, Columbus, OH 43215, USA.
American Journal of Surgery
|November 27, 2001
Summary
Completion axillary dissection (CAD) may not be necessary for breast cancer patients with micrometastasis in sentinel lymph nodes (SLN). Further studies are needed to confirm if SLN biopsy alone is sufficient for these patients.
Area of Science:
- Oncology
- Surgical Pathology
- Breast Cancer Research
Background:
- Sentinel lymph node biopsy (SLNB) is a standard procedure for staging breast cancer.
- Accurate assessment of lymph node involvement is crucial for treatment planning.
- The role of completion axillary dissection (CAD) in cases of micrometastasis is debated.
Purpose of the Study:
- To evaluate the necessity of completion axillary dissection (CAD) in breast cancer patients with micrometastasis (<2 mm) detected in sentinel lymph nodes (SLN).
- To determine if SLN biopsy alone is sufficient for staging in this specific patient subset.
Main Methods:
- Retrospective chart review of 227 breast cancer patients undergoing SLN mapping (SLNM) between 1998 and 2001.
- Intraoperative lymphatic mapping using blue dye and/or technetium-labeled sulfur colloid.
- SLN assessment via intraoperative touch preparation/frozen section and subsequent permanent hematoxylin and eosin staining.
Main Results:
- Of 226 successful SLNM procedures, 67 patients (27%) had macrometastasis requiring CAD, with 51% showing further axillary disease.
- Fifteen patients (6.7%) were diagnosed with micrometastasis.
- None of the 15 patients with micrometastasis showed evidence of local recurrence after a mean follow-up of 13.5 months, regardless of whether CAD was performed.
Conclusions:
- Completion axillary dissection (CAD) may not be required for breast cancer patients with micrometastasis identified in sentinel lymph nodes (SLN).
- Sentinel lymph node biopsy (SLNB) alone might be sufficient for staging in this subgroup.
- Larger, randomized prospective studies with long-term follow-up are essential to validate these findings.